Castle Q2 revenue $34.8M (+53%); raises 2022 guidance to $130-135M

CASTLE BIOSCIENCES INC

2022-Q2 EPS reported -$1.02 revenue$61,690,000

Q2 total test reports 11,034 (+57% YoY); skin cancer GEP volume up 44% YoY.
Net loss $(1.6)M improved from $(8.8)M; adjusted EBITDA $(10.9)M vs $(3.4)M.
2022 revenue guidance raised to $130-135M from $118-123M; cash $273M.
DecisionDx-Melanoma test linked to 27% improvement in melanoma-specific survival in NCI collaboration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.